动态适形弧治疗肺立体定向消融放疗后的临床结局与肺毒性:单机构队列研究
该单机构回顾性队列纳入145例原发或继发性肺肿瘤患者共152个病灶,采用动态适形弧治疗(DCAT)实施肺立体定向消融放疗(SABR),中位随访12个月,1年局部控制率96.7%、总生存率93.1%,仅7例(4.6%)出现2级症状性放射性肺炎,作者认为该技术局部控制有效且肺毒性低,与其他SABR技术相似。
要点
- 145例患者152个病灶接受DCAT-SABR,中位随访12个月,1年局部控制率96.7%、总生存率93.1%。
- 平均处方剂量BED10为110 Gy,92%患者处方剂量超过100 Gy BED10,平均PTV覆盖95.1%。
- 1级放射性肺炎66例(43%),2级症状性放射性肺炎仅7例(4.6%)。
核心结论
- 作者认为,采用动态适形弧治疗的肺SABR对原发或转移性肺肿瘤局部控制有效且肺毒性低,与其他SABR技术相似。
- 作者认为,DCAT-SABR是治疗肺部病灶的安全技术,可限制分次内运动、可能更好地保护危及器官并缩短束流照射时间。
研究设计与样本
- 单机构回顾性队列研究,回顾性识别接受DCAT-SABR治疗的原发或继发性肺肿瘤成年患者。
- 共145例患者符合纳入标准,合计152个病灶,中位随访12个月。
- 报告患者的临床、影像、组织学特征及剂量学参数。
主要发现
- 照射部位1年局部控制率为96.7%,1年总生存率为93.1%。
- BED10平均处方剂量为110 Gy,92%患者处方剂量超过100 Gy BED10。
- 平均PTV覆盖为95.1%。
- 1级放射性肺炎66例(43%),2级症状性放射性肺炎7例(4.6%)。
关键数值与推荐
- 95%患者总剂量分3次或5次照射,处方于80%等剂量线至PTV外周。
- BED10平均处方剂量110 Gy,92%患者处方剂量超过100 Gy BED10。
- 平均PTV覆盖95.1%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic ablative radiotherapy (SABR) is a validated treatment for early stage lung cancer and pulmonary metastases. It provides a high local control rate with low symptomatic toxicities. Recently, Dynamic Conformal Arc Therapy (DCAT), a delivery option that differs from conventional DCA, has been implemented in the Monaco Treatment Planning System for SABR. The aim of the study was to report clinical outcomes and toxicities for patients treated for lung SABR with this new technique. METHODS: We retrospectively identified adult patients treated for primary or secondary lung tumors with DCAT-SABR and reported their clinical, radiological, histological characteristics and dosimetric parameters. Total dose was delivered in 3 or 5 fractions for 95% of patients and prescribed on the 80% isodose line to the PTV periphery. RESULTS: 145 patients met inclusion criteria for a total of 152 lesions with a median follow up of 12 months. Local control for the irradiated site was 96.7% at 1 year. Overall survival was 93.1% at 1 year. Mean prescription dose in BED10 was 110 Gy. 92% of patients had a prescribed dose superior to 100 Gy BED10. Mean PTV coverage was 95.1%. There were 66 cases of grade 1 radiation pneumonitis (RP) (43%) and only 7 cases of symptomatic grade 2 RP (4.6%). CONCLUSION: Lung SABR for primary or metastatic lung tumors using dynamic conformal arc therapy provides efficient results of local control and low lung toxicities, similar to other SABR techniques. ADVANCES IN KNOWLEDGE: SABR using DCAT is a safe technique to treat lung lesions, allowing intra-fraction motion limitation, potentially higher OARs protection and a shortened beam delivery.
引用
- Mesny E, Ayadi M, Dupuis P, et al. Clinical outcomes and lung toxicities after lung SABR using dynamic conformal arc therapy: a single-institution cohort study. Radiat Oncol. 2023. PMID: 36814265. doi:10.1186/s13014-023-02227-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。